In particular, blockade of VEGF has shown clinical utility in the oncology setting as well as several retinal vascular diseases characterized by abnormal angiogenesis and/or vascular permeability, such as the “wet” form of age-related macular degeneration (AMD), the leading cause of blindness in the elderly [4, 5]. The gene discussed is VEGFA; the disease is age-related macular degeneration.